Influenza roadmap:
Vaccines
Roadmap for the development of candidate vaccines for influenza
Download Influenza-vaccine-development-roadmap7
Vectored vaccines
Vectored vaccines
Research Question
- Safe vectored vaccines
Research Gaps and Challenges
- Issues with environmental release and GMO
- Identity of suitable vector
- Anti-vector responses if reused
- Current vaccines are mostly directed to a single antigen (HA)
- Lack of streamlined regulations for live vectored vaccines proven safe (e.g HVT, FPV)
- Increased cost to license is limiting the updates of vaccines
- Potential spill over into non-targeted species
- Mass administration (some practical, some are not)
Solution Routes
- Intensify research focused on novel viral vectors that provide robust immune response, drastic reduction of shedding and can be mass administered in the field
- Flexibility on vector choice to avoid anti-vector responses if reused: for
instance, one for prime, a different one for boost - New technologies and improvement of current vectored vaccines
Dependencies
- Identity of protective antigens and their genetic code – multiple antigens needed
- Identity of suitable vectors
- Safety for live vectored vaccines platforms
- Better understanding of balanced immune responses would lead to vaccines with additional viral antigen components
State Of the Art
- Mixture of two or more separate rHVT as mixture expressing different antigens do not equally work together
Projects
What activities are planned or underway?
Development of Vaccines for HPAI in Cattle, Turkey, Pigs, and Small Ruminants and Food Safety Studies Related to HPAI Virus in Food Products
Planned Completion date 25/08/2029
Source Countries:
United States
Alternatives to Antibiotics: Neonatal Immunomodulation to Improve Disease Resistance in Animals
Planned Completion date 31/05/2026
Source Countries:
United States